Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 39 from EUR 41 and keeps an Underweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Reports Strong Q3 2025 Growth
- Fresenius Medical Care Reports Strong Q3 Earnings
- Fresenius Medical reports Q3 adjusted EPS EUR1.10 vs. EUR0.81 last year
- Fresenius Medical still sees 2025 revenue growth in low-single digits
- Fresenius Medical Care Reports Strong Q3 2025 Results and Strategic Progress